Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy

Neurol Sci. 2023 Oct;44(10):3679-3685. doi: 10.1007/s10072-023-06859-w. Epub 2023 Jun 2.

Abstract

Background: Early diagnosis of hereditary ATTR polyneuropathy (ATTRv-PN) is important since treatment options have become available, which are most effective early in the disease course. ATTRv-PN is likely underdiagnosed as patients might be misdiagnosed with idiopathic polyneuropathy. It is uncertain if it is useful to test for TTR gene mutations in patients with a typical presentation for chronic idiopathic axonal polyneuropathy (CIAP) and which are the distinguishing clinical features.

Methods: We carried out a retrospective cohort study to assess the yield of TTR gene sequencing in patients with polyneuropathy and assessed if the identified patients with ATTRv-PN had a clinical presentation typical of CIAP. Additionally, we assessed which clinical features, including previously defined red flag symptoms, can differentiate between patients with CIAP and ATTRv-PN and assessed the performance of the TTR suspicion index.

Results: Out of 338 patients with polyneuropathy, 10 patients had a pathogenic TTR gene mutation (all p.Val50Met) and none had a clinical presentation typical of CIAP. Patients with ATTRv-PN more often had bilateral CTS, motor involvement of arms, cardiac involvement, family history suggestive of hATTRv, and autonomic symptoms than patients with CIAP. All patients with ATTRv-PN as well as 70% of patients with CIAP fulfilled the suspicion index.

Conclusion: Routine TTR gene sequencing in patients with a typical presentation for CIAP is not useful. However, red flag symptoms can differentiate patients with ATTRv-PN from patients with CIAP. We propose an adjusted version of the TTR suspicion index to increase diagnostic yield.

Keywords: ATTR; ATTRv-PN; Amyloidosis; Genetics; Neuropathy; Polyneuropathy; Transthyretin.

MeSH terms

  • Amyloid Neuropathies, Familial* / diagnosis
  • Amyloid Neuropathies, Familial* / genetics
  • Disease Progression
  • Humans
  • Polyneuropathies* / diagnosis
  • Polyneuropathies* / genetics
  • Prealbumin / genetics
  • Retrospective Studies

Substances

  • Prealbumin

Grants and funding